<DOC>
	<DOC>NCT00207155</DOC>
	<brief_summary>The purpose of this study is to predict response to Erbitux as a single agent in patients with metastatic colon cancer</brief_summary>
	<brief_title>An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Measurable disease Tumor available for biopsies. Life expectancy of at least 3 months. Known or documented brain metastases prior to Cetuximab therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>